Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

Article

Abstract: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoi

Palabras claves:

Conjugate-vaccine, COVID-19 Vaccine, Heterologous scheme, RBD-subunit vaccine, SARS-COV-2, Vaccine efficacy

Autores:

Bacallao-Castillo J.P., Baldoquín-Rodríguez W., Biglari A., Caballero-González E., Climent-Ruiz Y., Doroud D., Duartes-González R., Egües-Torres L., Fernández-Castillo S., Fonte-Galindo O., García-Blanco S., García-Carmenate M., García-Rivera D., González-Mujica Romero R., Gouya M.M., Herrera-Marrero N., Huete-Ferreira S., Idalmis-Cisnero K., Licea-Martín E., Martínez-Pérez M., Meliá-Pérez D., Mendoza-Hernández I., Misladys Rodríguez Ortega, Paredes-Moreno B., Pérez-Cabrera S., Rodríguez-González M., Rojas-Remedios I., Samón-Tabio O., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Van Der Stuyft P., Velazco-Villares P., Verez-Bencomo V.

Fuentes:

scopus